Empowered Patient Podcast

Dr. Mike McCullar, CEO of RegCell, is developing a novel cell therapy to treat autoimmune diseases that specifically addresses the loss of tolerance, in which the immune system mistakenly attacks the body's own tissues. This approach contrasts with current treatments, which broadly suppress the immune system and may cause side effects. The key goals of the therapy are to achieve long-term disease control and restore the immune system's natural balance. The company's manufacturing process is designed to simplify cell therapies, making them more affordable and accessible to a broader population of autoimmune patients. Mike explains, "The real driver of immunity, we believe, is what's called loss of tolerance, which is a system in our bodies that protects us from bad immune cells that attack our tissues. So that's a fundamental limitation in biology, and there really is not a curated treatment at this point. So our view has really been to try to restore the natural balance of our immune system by regulatory T c